GB2056280A - Normolipidemic or platelet anti-binder - Google Patents
Normolipidemic or platelet anti-binder Download PDFInfo
- Publication number
- GB2056280A GB2056280A GB8025197A GB8025197A GB2056280A GB 2056280 A GB2056280 A GB 2056280A GB 8025197 A GB8025197 A GB 8025197A GB 8025197 A GB8025197 A GB 8025197A GB 2056280 A GB2056280 A GB 2056280A
- Authority
- GB
- United Kingdom
- Prior art keywords
- binder
- platelet anti
- compound
- normolipidemic
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011230 binding agent Substances 0.000 title claims description 6
- 230000000444 normolipidemic effect Effects 0.000 title claims description 4
- KBFBRIPYVVGWRS-UHFFFAOYSA-N cloridarol Chemical compound C=1C2=CC=CC=C2OC=1C(O)C1=CC=C(Cl)C=C1 KBFBRIPYVVGWRS-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229960001261 cloridarol Drugs 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT7909513A IT1207887B (it) | 1979-08-10 | 1979-08-10 | Uso in terapia del prodotto (2benzofuril)-(p-clorofenil)-carbino lo(cloridarol dci)come normolipide mizzante e antiaggregante piastrinico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2056280A true GB2056280A (en) | 1981-03-18 |
Family
ID=11131363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8025197A Withdrawn GB2056280A (en) | 1979-08-10 | 1980-08-01 | Normolipidemic or platelet anti-binder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4296124A (enExample) |
| JP (1) | JPS5645413A (enExample) |
| BE (1) | BE884691A (enExample) |
| CA (1) | CA1155395A (enExample) |
| CH (1) | CH648756A5 (enExample) |
| DE (1) | DE3029421A1 (enExample) |
| FR (1) | FR2463135A1 (enExample) |
| GB (1) | GB2056280A (enExample) |
| IT (1) | IT1207887B (enExample) |
| LU (1) | LU82700A1 (enExample) |
| NL (1) | NL8004534A (enExample) |
| ZA (1) | ZA804822B (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1160925A (en) * | 1967-02-08 | 1969-08-06 | Menarini Sas | 2-Substituted Benzofuran Derivatives |
-
1979
- 1979-08-10 IT IT7909513A patent/IT1207887B/it active
-
1980
- 1980-08-01 GB GB8025197A patent/GB2056280A/en not_active Withdrawn
- 1980-08-02 DE DE19803029421 patent/DE3029421A1/de active Granted
- 1980-08-07 ZA ZA00804822A patent/ZA804822B/xx unknown
- 1980-08-08 LU LU82700A patent/LU82700A1/fr unknown
- 1980-08-08 BE BE0/201683A patent/BE884691A/fr not_active IP Right Cessation
- 1980-08-08 JP JP10839080A patent/JPS5645413A/ja active Granted
- 1980-08-08 CH CH6040/80A patent/CH648756A5/it not_active IP Right Cessation
- 1980-08-08 NL NL8004534A patent/NL8004534A/nl not_active Application Discontinuation
- 1980-08-11 CA CA000357982A patent/CA1155395A/en not_active Expired
- 1980-08-11 FR FR8017691A patent/FR2463135A1/fr active Granted
- 1980-08-11 US US06/176,867 patent/US4296124A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4296124A (en) | 1981-10-20 |
| CA1155395A (en) | 1983-10-18 |
| DE3029421A1 (de) | 1981-02-26 |
| CH648756A5 (it) | 1985-04-15 |
| NL8004534A (nl) | 1981-02-12 |
| IT1207887B (it) | 1989-06-01 |
| BE884691A (fr) | 1980-12-01 |
| DE3029421C2 (enExample) | 1990-02-22 |
| LU82700A1 (fr) | 1980-12-15 |
| FR2463135B1 (enExample) | 1983-08-12 |
| ZA804822B (en) | 1981-08-26 |
| JPH0153244B2 (enExample) | 1989-11-13 |
| FR2463135A1 (fr) | 1981-02-20 |
| IT7909513A0 (it) | 1979-08-10 |
| JPS5645413A (en) | 1981-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| DE68902581T2 (de) | Pharmazeutische zusammensetzungen mit krebshemmender wirkung. | |
| US4628047A (en) | Agent for enhancing antitumor activity of antitumor agent | |
| DE4307508A1 (de) | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) | |
| KR880000191B1 (ko) | 급성방사선 증후군 발현억제 및 패혈증 발현억제 조성물 | |
| EP0374096B1 (de) | 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür | |
| DE69534745T2 (de) | Immunopotenzierende 5'-nucleotidase-resistente inosinmonophosphat-derivate und ihre verwendung | |
| US2761807A (en) | Glycocyamine and methylating agent in vivo creatine producing composition | |
| AU693076B2 (en) | Arsenic medicaments for the treatment of chronic fatigue syndrome | |
| DE19544768C1 (de) | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose | |
| US4343799A (en) | Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity | |
| Carpenter et al. | Chemotherapy of murine leprosy | |
| US4296124A (en) | Pharmaceutical methods | |
| DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
| AT408719B (de) | Mittel zur behandlung von hepatitis c | |
| Ehninger et al. | Mitoxantrone in the treatment of relapsed and refractory acute leukemia | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| Funcke et al. | Protective action of cyclandelate in hypoxia | |
| DE3410848A1 (de) | Arzneimittel zur behandlung von tumoren in der metastasenphase | |
| Faergeman | Effects and side‐effects of treatment of hypercholesterolemia with cholestyramine and neomycin | |
| DE69019148T2 (de) | D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren. | |
| US5126149A (en) | Method of inducing the production of cytokines | |
| DE69409553T2 (de) | Zytotoxische Verbindungen | |
| DE2334358A1 (de) | Pharmazeutische zubereitungen mit neuartiger wirkung | |
| DE69332982T2 (de) | Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |